The Patent Finder

Merck Serono S.A.

31 patents currently held · Updated Nov 15, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

21
Ending by 2030
May 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Jan 7 to 9, 2027 · next Jan 7
  • 1 fee due May 3, 2027
    The maintenance fee for Puro-DHFR quadrifunctional marker and its use in protein production (US 9,175,284) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
  • 1 fee due Nov 5, 2027
    The maintenance fee for Nucleic Acid Molecules Encoding Humanized IL-31 Monoclonal Antibodies (US 10,640,559) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,555,913Cladribine regimen for treating multiple sclerosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,772,233Novel Arylamino N-Heteroaryl Compounds as Mek Inhibitors
In force
 · High confidence
In forceHigh confidence
US 7,879,888Thiazole derivatives and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,877,757Pyrazine derivatives and use as PI3K inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,357,535PURO-DHFR quadrifunctional marker and its use in protein production
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,841,106Puro-DHFR quadrifunctional marker and its use in protein production
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,175,284Puro-DHFR quadrifunctional marker and its use in protein production
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,956,1913-Arylamino Pyridine Derivatives
In force
 · High confidence
In forceHigh confidence
US 12,377,056Cladribine regimen for treating multiple sclerosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,685,669Nucleic Acid Molecules Encoding Humanized Antibody Molecules Specific for IL-31
In force
 · High confidence
In forceHigh confidence
10 of 31 patents shown.
Pro members see all 31.
Pro members: see all 31 patents
Also on record, not counted in the 31: 4 patents in force now held by others · 182 lapsed for an unpaid fee · 92 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 abandoned · 28 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited